Search

The Valencia-based company, founded nearly four years ago, moves away from the content marketing agency model to launch a comprehensive digital go-to-market system designed specifically for B2B

The startup receives $15,000 award for its innovative MP-004 therapy targeting retinitis pigmentosa.

The Spanish biotech company opens a new business line to apply its expertise in advanced lipid-based systems to the development of solutions for cosmetic ingredients.

On May 21, the new BIOFISH 7000 TVBN device was unveiled in Lima as a world premiere, designed to measure fish freshness in an objective, fast, and simple way.

Rising life expectancy and increasing pressure on healthcare and social systems are driving a new market focused on prevention, independence, and quality of life for older adults.

BCN HEALTH will participate in the Jornadas AES, which will take place in Seville from June 17 to 19.

The new unit will be headed by Pablo Estebaranz Ruiz, an electronics engineer and European Patent Attorney (EPA)with over 18 years of experience.

The company has been recognised for the European project SustaiNext and its DYANA technology, a pioneering intelligent biorefinery model based on the circular economy.

Autónoma University of Madrid and Complutense University of Madrid founded the science incubator in 2001.

The biomedical Company MSD, a leader in research, has reached a new milestone in its commitment to science and innovation in Spain.

Asabys launches a fund of up to €120M to transform scientific discoveries into innovative healthcare companies, reinforcing its commitment to technology transfer and the creation of deep tech

Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-off.

Partnership during the last 8 years leverages VIVEbiotech’s decade of experience manufacturing GMP ex- and in- vivo lentiviral vectors for the advanced therapies sector.

Transfection-free stable producer cell line (SCL) offers easy scalability, reduction of cost of goods (COGs), improve vector quality, and low batch variability.

We welcome the Biotech Act I, but believe its ambition and level of specificity must be strengthened to ensure a real impact on funding, industrial scale-up, and biotechnology innovation in Europe; a

Rubén Pérez-Mañanes is an orthopaedic oncology surgeon at the HGUGM (Gregorio Marañón University General Hospital), deputy director of the Gregorio Marañón Health Research Institute and an ANECA

Meet StablePharma, our new member. We spoke with Lorena Carmona Rodríguez, Lab Manager/Senior Scientist.